The mortality effects of disregarding the strategy to save doses of measles vaccine: a cluster-randomised trial in Guinea-Bissau.

child health epidemiology immunisation public health vaccines

Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
05 2021
Historique:
received: 01 11 2020
revised: 31 03 2021
accepted: 16 04 2021
entrez: 4 5 2021
pubmed: 5 5 2021
medline: 25 6 2021
Statut: ppublish

Résumé

Measles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials, children in Guinea-Bissau are only measles vaccinated when aged 9-11 months and when six or more children are present. We assessed health impacts of providing MV to all measles-unvaccinated children 9-35 months. We cluster-randomised 182 village clusters under demographic surveillance in rural Guinea-Bissau to an 'MV-for-all-policy' arm where we offered MV regardless of age and number of children present at our bi-annual village visits, or a 'Restrictive-MV-policy' arm where we followed national policy. Measles-unvaccinated children aged 9-35 months were eligible for enrolment and followed to 5 years of age. In intention-to-treat analyses, we compared mortality using Cox regression analyses with age as underlying timescale. The primary analysis was for children aged 12-35 months at eligibility assessment. Interactions with several background factors were explored. Between 2011 and 2016, we followed 2778 children in the primary analysis. MV coverage by 3 years was 97% among children eligible for enrolment under the MV-for-all-policy, and 48% under the Restrictive-MV-policy. Mortality was 59% lower than anticipated and did not differ by trial arm (MV-for-all-policy: 45/1405: Restrictive-MV-policy: 44/1373; HR: 0.95 (95% CI 0.64 to 1.43)). The effect of MV-for-all changed over time: The HR was 0.53 (95% CI 0.27 to 1.07) during the first 1½ years of enrolment but 1.47 (95% CI 0.87 to 2.50) later (p=0.02, test of interaction). Explorative analyses indicated that the temporal change may be related to interactions with other childhood interventions. The MV-for-all-policy increased MV coverage but had no overall effect on overall mortality. NCT01306006.

Identifiants

pubmed: 33941513
pii: bmjgh-2020-004328
doi: 10.1136/bmjgh-2020-004328
pmc: PMC8098964
pii:
doi:

Substances chimiques

Measles Vaccine 0

Banques de données

ClinicalTrials.gov
['NCT01306006']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Infect Dis. 2021 May 18;72(10):e596-e603
pubmed: 32949460
J Infect Dis. 2014 Jun 1;209(11):1731-8
pubmed: 24436454
Pediatr Infect Dis J. 2010 Apr;29(4):324-8
pubmed: 19934785
BMJ Open. 2019 Jun 11;9(6):e028775
pubmed: 31189684
Pediatr Infect Dis J. 2006 Aug;25(8):721-7
pubmed: 16874172
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
Lancet. 2003 Nov 22;362(9397):1765
pubmed: 14643138
Clin Infect Dis. 2018 May 2;66(10):1573-1580
pubmed: 29177407
BMJ Open. 2016 Dec 23;6(12):e013335
pubmed: 28011813
Pediatr Infect Dis J. 2003 Sep;22(9):798-805
pubmed: 14506371
Pediatr Infect Dis J. 2015 Dec;34(12):1369-76
pubmed: 26379164
Semin Pediatr Infect Dis. 2003 Jul;14(3):220-32
pubmed: 12913835
BMJ Open. 2016 Dec 20;6(12):e011317
pubmed: 27998896
BMC Public Health. 2019 Nov 11;19(1):1506
pubmed: 31711464
BMJ. 2000 Dec 9;321(7274):1435-8
pubmed: 11110734
Lancet. 2003 Jun 28;361(9376):2183-8
pubmed: 12842371
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
BMJ. 1995 Aug 19;311(7003):481-5
pubmed: 7647643
Lancet Glob Health. 2014 Aug;2(8):e478-87
pubmed: 25103521
Trop Med Int Health. 2017 Jan;22(1):12-20
pubmed: 27717100
Lancet Infect Dis. 2020 Oct;20(10):e274-e283
pubmed: 32645296
Front Public Health. 2018 Feb 02;6:13
pubmed: 29456992
Pediatr Infect Dis J. 2016 Nov;35(11):1232-1241
pubmed: 27753769
Vaccine. 2017 Jan 3;35(1):33-39
pubmed: 27890397
Vaccine. 2014 Jan 23;32(5):598-605
pubmed: 24325827

Auteurs

Stine Byberg (S)

Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Bandim Health Project, OPEN, University of Southern Denmark, Copenhagen, Denmark.
Research Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen, Denmark.
Steno Diabetes Center Copenhagen, Gentofte, Denmark.

Peter Aaby (P)

Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Bandim Health Project, OPEN, University of Southern Denmark, Copenhagen, Denmark.
Research Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen, Denmark.

Amabelia Rodrigues (A)

Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.

Christine Stabell Benn (C)

Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau.
Bandim Health Project, OPEN, University of Southern Denmark, Copenhagen, Denmark.
Research Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen, Denmark.
Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark.

Ane Baerent Fisker (AB)

Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau afisker@health.sdu.dk.
Bandim Health Project, OPEN, University of Southern Denmark, Copenhagen, Denmark.
Research Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH